Impact of vitamin D levels on disease activity, function and health over 2 years in radiographic axial spondyloarthritis: data from GErman SPondyloarthritis Inception Cohort (GESPIC)
Open Access
Abstract
Objectives: To investigate the impact of vitamin D on disease activity, function and health in patients with radiographic axial spondyloarthritis (r-axSpA) undergoing biological disease-modifying antirheumatic drug (bDMARD) therapy. Methods: Patients with r-axSpA and active disease at baseline initiating a bDMARD were included in this analysis. Vitamin D (25-hydroxyvitamin D) was measured at baseline and every 6 months until year 2; deficiency was defined as <20 ng/mL. The outcomes were AxSpA Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Patient Global Assessment (PGA), Bath Ankylosing Spondylitis Functional Index (BASFI), Assessment of SpondyloArthritis international Society Health Index (ASAS-HI) and C reactive protein (CRP). Longitudinal associations were evaluated using generalised estimating equations, with sensitivity analyses accounting for time-varying confounders. Results: We analysed 122 patients (mean age 36.6 (10.3) years; 66.4% male), of whom 53.3% had vitamin D deficiency at baseline. In longitudinal models, normal vitamin D levels were associated with lower ASDAS (β per 1 ng/mL increase: −0.010; 95% CI −0.017 to −0.003), BASDAI (β: −0.021; 95% CI −0.036 to −0.006), PGA (β: −0.021; 95% CI −0.039 to −0.003) and BASFI (β: −0.015; 95% CI −0.032 to 0.001). Effect estimates of ASDAS, BASDAI, BASFI, CRP (and their corresponding categorical outcomes) were attenuated in sensitivity analyses but remained directionally consistent. Positive associations with PGA and ASAS-HI were also observed though the estimates were not consistent through all models. Conclusions: Normal vitamin D levels were modestly associated with lower disease activity in r-axSpA treated with bDMARDs. Monitoring and optimising vitamin D status may support better disease control.Keywords
Funding Information
- Berlin Institute of Health
- UCB Pharma
- German Federal Ministry of Education and Research
- Eli Lilly
- Johnson and Johnson
- AbbVie
This publication has 14 references indexed in Scilit:
- Understanding the causes of treatment failure is crucial for the management of axial spondyloarthritisNature Reviews Rheumatology, 2025
- Vitamin D and its analogs in immune system regulationPharmacological Reviews, 2024
- Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working groupAging Clinical and Experimental Research, 2022
- Vitamin D supplementation in systemic lupus erythematosus: relationship to disease activity, fatigue and the interferon signature gene expressionBMC Rheumatology, 2021
- Axial spondyloarthritisThe Lancet, 2017
- Cell‐type‐specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytesImmunology, 2016
- The vitamin D status in ankylosing spondylitis in relation to intestinal inflammation, disease activity, and bone health: a cross-sectional studyOsteoporosis International, 2016
- Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitisRheumatology, 2014
- Control of autoimmune diseases by the vitamin D endocrine systemNature Clinical Practice Rheumatology, 2008
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984